Risk Factors and Prognoses in Patients Hospitalized for COVID-19
1 other identifier
observational
971
1 country
2
Brief Summary
Multicenter and observational study. The study will include patients admitted to hospitals in the Lleida health region with confirmed COVID-19. Follow-up will be carried out up to six months after hospital discharge. Through the analysis of clinical data and biological parameters, it is possible to identify in advance patients who will evolve in an unfavorable prognosis in relation to COVID-19, either because they present criteria of severe disease or because they present thrombotic complications associated with the disease. The final aim is to make anticipated and individualized therapeutic decisions that reduce the morbidity and mortality associated with the disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 18, 2020
CompletedFirst Submitted
Initial submission to the registry
March 24, 2021
CompletedFirst Posted
Study publicly available on registry
April 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedNovember 22, 2023
November 1, 2023
2.6 years
March 24, 2021
November 21, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Composite endpoint (death, initiation of mechanical ventilation, ICU admission and thrombotic event)
Development of a predictive model of adverse events (death, initiation of mechanical ventilation, ICU admission and thrombotic event).
18 months
Secondary Outcomes (4)
Death
18 months
Mechanical ventilation
18 months
ICU admission
18 months
Thrombotic event
18 months
Interventions
Hospital treatment of COVID disease
Eligibility Criteria
Patients admitted to the participating centers of the Lleida health region, with a positive laboratory diagnosis for COVID19.
You may qualify if:
- Laboratory confirmed COVID-19 infection.
- Hospitalization in a center in the Lleida healthcare region.
You may not qualify if:
- Patients admitted with repeatedly negative COVID-19 test results.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Hospital Universitari Arnau de Vilanova
Lleida, 25198, Spain
Hospital Universitari Santa Maria
Lleida, 25198, Spain
Related Publications (1)
Belmonte T, Perez-Pons M, Benitez ID, Molinero M, Garcia-Hidalgo MC, Rodriguez-Munoz C, Gort-Paniello C, Moncusi-Moix A, Made A, Devaux Y, Martelli F, Ortega A, Gonzalez J, Torres G, Barbe F, de Gonzalo-Calvo D. Addressing the unsolved challenges in microRNA-based biomarker development: Suitable endogenous reference microRNAs for SARS-CoV-2 infection severity. Int J Biol Macromol. 2024 Jun;269(Pt 2):131926. doi: 10.1016/j.ijbiomac.2024.131926. Epub 2024 Apr 28.
PMID: 38688344DERIVED
Biospecimen
1 tube EDTA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ferran Barbé, MD
Spanish Respiratory Society (SEPAR)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chair Respiratory Medicine
Study Record Dates
First Submitted
March 24, 2021
First Posted
April 1, 2021
Study Start
May 18, 2020
Primary Completion
December 31, 2022
Study Completion
December 31, 2022
Last Updated
November 22, 2023
Record last verified: 2023-11